HRT containing drospirenone launched
Hormone replacement therapy with drospirenone is now available from Schering Health Care.
Angeliq (estradiol 1mg and drospirenone 2mg) is licensed for oestrogen
deficiency symptoms in postmenopausal women more than one year post menopause.
It is also licensed for the prevention of osteoporosis in postmenopausal
women at high risk of future fractures who are intolerant of other products
approved for the prevention of osteoporosis or in whom these products
are contraindicated.
The company says that the pharmacodynamic profile of drospirenone, the
progestogen used in the hormonal contraceptive Yasmin but not previously
used in HRT, resembles a woman’s natural progesterone more closely
than other synthetic progestogens, and its anti-mineralocorticoid activity
may help to reduce the likelihood of fluid retention and bloating. |
The
Pharmaceutical Journal
Acrobat
Reader